Literature DB >> 16131946

Differential response to combined treatment in patients with psychotic versus nonpsychotic major depression.

Brandon A Gaudiano1, Christopher G Beevers, Ivan W Miller.   

Abstract

Research has demonstrated that depressed patients with psychotic features show poorer outcomes when treated with pharmacotherapy alone compared with those without psychotic features. However, research has not investigated whether this differential response also applies to combined treatment that includes pharmacotherapy and psychotherapy. In the current study, data were pooled from two clinical trials in which patients diagnosed with major depressive disorder with or without psychotic features were treated with combined treatment. Although similar in severity at pretreatment, results indicated that patients with psychotic depression showed a poorer response in terms of depression severity at postoutpatient treatment and at 6-month follow-up compared with those with nonpsychotic depression. Following treatment, patients with psychotic depression were over four times as likely to exhibit high levels of depression and suicidal ideation. Current state-of-the-art combined treatments have poorer efficacy in depressed patients with psychotic symptoms, and adapted treatment approaches are needed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131946     DOI: 10.1097/01.nmd.0000177791.33649.69

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  13 in total

Review 1.  Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?

Authors:  Mitchel A Kling; Victoria H Coleman; Jay Schulkin
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

2.  Does comorbid posttraumatic stress disorder affect the severity and course of psychotic major depressive disorder?

Authors:  Brandon A Gaudiano; Mark Zimmerman
Journal:  J Clin Psychiatry       Date:  2009-12-15       Impact factor: 4.384

3.  Psychotic depression, posttraumatic stress disorder, and engagement in cognitive-behavioral therapy within an outpatient sample of adults with serious mental illness.

Authors:  Jennifer D Gottlieb; Kim T Mueser; Stanley D Rosenberg; Haiyi Xie; Rosemarie S Wolfe
Journal:  Compr Psychiatry       Date:  2010-07-02       Impact factor: 3.735

4.  Diagnostic consistency of major depression with psychosis across 10 years.

Authors:  Camilo J Ruggero; Roman Kotov; Gabrielle A Carlson; Marsha Tanenberg-Karant; David A González; Evelyn J Bromet
Journal:  J Clin Psychiatry       Date:  2011-08-09       Impact factor: 4.384

Review 5.  Rating scales measuring the severity of psychotic depression.

Authors:  S D Østergaard; A J Rothschild; A J Flint; B H Mulsant; E M Whyte; A K Leadholm; P Bech; B S Meyers
Journal:  Acta Psychiatr Scand       Date:  2015-05-27       Impact factor: 6.392

6.  An open trial of a new acceptance-based behavioral treatment for major depression with psychotic features.

Authors:  Brandon A Gaudiano; Kathryn Nowlan; Lily A Brown; Gary Epstein-Lubow; Ivan W Miller
Journal:  Behav Modif       Date:  2012-12-06

7.  Prevalence and clinical characteristics of psychotic versus nonpsychotic major depression in a general psychiatric outpatient clinic.

Authors:  Brandon A Gaudiano; Kristy L Dalrymple; Mark Zimmerman
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

Review 8.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

9.  Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression.

Authors:  Brandon A Gaudiano; Diane Young; Iwona Chelminski; Mark Zimmerman
Journal:  Compr Psychiatry       Date:  2008-03-28       Impact factor: 3.735

10.  Does the dexamethasone suppression test reliably discriminate between psychotic and nonpsychotic major depression?: an exploratory analysis of potential confounds.

Authors:  Brandon A Gaudiano; Gary Epstein-Lubow; Ivan W Miller
Journal:  J Nerv Ment Dis       Date:  2009-06       Impact factor: 2.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.